

LeadAction Ovarian Cancer Competition

Frequently Asked Questions

PROJECT ELIGIBILITY

Can I consider the expertise of a research laboratory as an expertise equivalent to a specialized drug discovery core facility (platform)?

A specialized core facility with emphasis on drug development, facilitates and accelerates development of small molecules or biotherapies using several different approaches from the molecular biology to the preclinical and sometimes clinical expertise. Expertise acquired within a laboratory cannot replace the global services proposed by a specialized drug discovery core facility.

Is it an obligation to use services from the Institute for Research in Immunology and Cancer (IRIC) core facilities if we want to apply to the LeadAction Ovarian Cancer Competition?

Applicants who need to use drug discovery core facilities are invited to refer to those referenced in the annex of the competition's guidelines (**ANNEX: Locations offering drug discovery services**). However, applicants remain free to consider specialized drug discovery core facilities of his/her choice.

Which stages are eligible and fundable in the LeadAction Ovarian Cancer Competition for a biotherapy?

For the development of small molecules, eligible and fundable translational research activities used to develop biotherapy projects, are the same.

Are diagnostic projects or platforms eligible at the LeadAction Ovarian Cancer Competition?

Eligible projects to the LeadAction Ovarian Cancer Competition are related to the development of small molecules or biotherapies (antibodies, oncolytic viruses, cell products such as stem cells or T cells, synthetic peptides, ribonucleic acid (RNA)-based approaches, etc.). This list is non-exhaustive, but research on diagnostic projects or platforms is not eligible.

If I use a service from a specialized drug discovery core facility located in my Institution, do I have to include a quote in my complete application?

For all services from drug discovery core facilities, a quote must be included in the complete application.

APPLICANTS' ELIGIBILITY

Is it mandatory to have a collaboration with a Principal Investigator from IRIC to submit a project to the LeadAction Ovarian Cancer Competition?

It is not mandatory to add a Principal Investigator from IRIC in the research team to submit a project to the LeadAction Ovarian Cancer Competition.

Can I apply to the LeadAction Ovarian Cancer Competition without Collaborators affiliated with a Quebec institution?

The grantee (Principal Investigator) must be a University Investigator or a Clinical University Investigator from an institution, centre, research institute or department affiliated with a Canada-based university. A Quebec-based collaborator/co-investigator is not required.

REQUIRED DOCUMENTS

What kind of information should be indicated in the letter of support from the administrators of the Institution or university department in which the Principal Investigator's research will be carried out?

The letter of support must mention that the administrators of the Institution or university department in which the Principal Investigator's research will be carried out are committed to support the Principal investigator through administrative support and access to facilities to ensure the success of the project.

AMOUNT OF THE GRANT

Can I manage in parallel hit to lead transition activities and lead optimization activities?

Hit to lead transition activities and lead optimization activities can be managed in parallel.

Can I manage in parallel lead optimization activities and preclinical studies?

Lead optimization activities and preclinical studies can be managed in parallel.

CONFIDENTIALITY

Do I have to include confidential information in the notice of intent/complete application?

It remains the responsibility of the Principal Investigator to present necessary and sufficient information allowing the review Committee to assess the project.

All information from the notice of intent/complete application transmitted to the Promoters of the LeadAction Ovarian Cancer Competition and to the review Committee, will be processed with complete confidentiality, in compliance with the policies of IRICoR and the Competition guidelines.